1. Pink Sheet
  2. >>Legal & IP
  3. >>Patents

IGBA Picks Apart Innovator Patent ‘Gaming Systems’

A New Report Illustrates Strategies Delaying Or Blocking Off-Patent Competition

 
• By Urtė Fultinavičiūtė

The International Generic and Biosimilar Medicines Association has introduced its first global intellectual property and competition report, addressing the urgent need to reform current regulations. But, in a bid to increase access to medicines across the world, did it stop short at just IP and patents?

Chess figures placed on map with connecting lines between them
The IGBA's report on patent abuse strategies covers multiple regions (Shutterstock)
Key Takeaways
  • A 123-page report from the International Generic and Biosimilar Medicines Association examines patent abuse strategies and highlights the different ways originators try to monopolize markets beyond the intended terms
  • The report analyzes seven evergreening practices: patent thickets, patent linkage, elimination of skinny labels, product hopping, pricing strategies, denigration, and misuse of regulatory procedures.
  • The IGBA highlights the need to reform current laws, regulations and practices, which make patent abuse strategies possible.

The International Generic and Biosimilar Medicines Association (IGBA) has released a first-of-its-kind report, delving deep into the nooks and crannies of patent abuse strategies, backed...

Titled ‘Gaming the system: An overview of originator companies’ evergreening strategies used to hinder access to generic and biosimilar products,” the 123-page report highlights the different ways originators try to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Patents

Supreme Court May Be Next After Federal Circuit Refuses To Rehear Teva Inhaler Patents Case

 
• By Urtė Fultinavičiūtė

Teva was forced to delist its ProAir HFA inhaler patents from the FDA’s Orange Book by mid-March after the Federal Circuit denied its petition for en banc rehearing. Will the Supreme Court listen?

Makary Signals Some Interest In US FDA Staff Cuts, Fighting Patent Thickets

 
• By Sarah Karlin-Smith

The FDA Commissioner nominee also commented on trial diversity, the role of public comment and expedited biosimilar reviews during his Senate confirmation hearing.

IGBA Picks Apart Innovator Patent ‘Gaming Systems’

 
• By Urtė Fultinavičiūtė

The International Generic and Biosimilar Medicines Association has introduced its first global intellectual property and competition report, addressing the urgent need to reform current regulations. But, in a bid to increase access to medicines across the world, did it stop short at just IP and patents?

PhRMA Kicks Off Year Attacking China, Wrapping Agenda In American Flag

 
• By Sarah Karlin-Smith

US pharma leadership is painting its mission, particularly its goal to end Medicare price controls, as patriotic and essential to America’s global dominance over China, a move that seems designed to align with President Trump’s priorities.

More from Legal & IP

EU Wants Industry To Define ‘Trade Secrets’ Under Health Data Sharing Regulation

 
• By Eliza Slawther

The European Health Data Space Regulation is deliberately “vague” when it comes to defining trade secrets because the EU wants the pharma industry to make recommendations on safeguarding intellectual property, a policy officer for the European Commission says.

Trump Administration Push For Dismissal, Transfer Of Mifepristone Case Leaves Overhang For Pharma

 
• By Sarah Karlin-Smith

The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.

Viatris Agrees To $335m Opioid Settlement Ending US State, Local Government Cases

 
• By Dean Rudge

Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.